Skip to content
You are now leaving to visit

Ionis Pharmaceuticals Announces Plans to Open Expanded Access Program to Provide Inotersen to Patients with Hereditary TTR Amyloidosis in the U.S.

– Ionis plans to open multiple sites in the U.S. CARLSBAD, Calif. , Oct. 27, 2017 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it plans to open an expanded access program (EAP) for eligible patients with hereditary transthyretin amyloidosis (hATTR) with